KRAS and familial pancreatic carcinoma: Thus, this study utilized untargeted metabolomic analysis to identify potential biomarkers and elucidate metabolic changes between KRAS-wildtype and -mutant pancreatic cancer cells to gain insights into overcoming treatment challenges in pancreatic cancer management.